Nama's AI scorecard currently rates Denali Therapeutics Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does DNLI report earnings?

Denali Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.57.

What is the DNLI price target?

The median analyst price target from 16 analysts is $36.00, with a range of $23.00 – $46.00.

Is DNLI Shariah compliant?

Nama's AAOIFI-style screen reads Denali Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Denali Therapeutics (DNLI)

Healthcare · Biotechnology · NASDAQ

Denali Therapeutics (DNLI) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.22B and a free-cash-flow yield of -12.2%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 3.4/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Rising · +33.0% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-64.0%

How far the last close sits under the highest price of the past five years.

Market cap	$3.22B
Trailing P/E	—
Price / book	3.8
Price / sales	1003.5
FCF yield	-12.2%
Dividend yield	—
Gross margin	0.0%
Operating margin	-3601.3%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	-100.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

DNLI earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.57). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	-$0.66	-$0.37	-78.4%	$17.78M
Q2 2026	Aug 6, 2026	-$0.68	-$0.47	-44.7%	$3.60M
Q1 2026	May 7, 2026	-$0.69	-$0.71	+2.8%	$0
Q4 2025	Feb 26, 2026	-$0.73	-$0.75	+2.7%	$0

DNLI analyst price target

Median target $36.00 from 16 analysts, ranging $23.00 – $46.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live DNLI data on Nama Insights →

DNLI FAQ

Is DNLI a buy?: Nama's AI scorecard currently rates Denali Therapeutics Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does DNLI report earnings?: Denali Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.57.
What is the DNLI price target?: The median analyst price target from 16 analysts is $36.00, with a range of $23.00 – $46.00.
Is DNLI Shariah compliant?: Nama's AAOIFI-style screen reads Denali Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.